Irish biotech Amarin gears up for drug launch in Europe
Company’s cardiovascular drug should be cleared in next six weeks for EU use
Irish heart drug group Amarin slumps 70% over patent suit loss
Nevada court rules patents are invalid in crunch battle with generic rivals
Irish pharma group says sales of heart drug will top projections
Amarin doubling size of US sales force as FDA sanctions expanded market for Vascepa
Winners and losers in a year of extremes in the business world
Green Reit and CRH among winners as Boeing, Denis O’Brien and RTÉ join losers
Amarin secures European review for cardio drug Vascepa
Purified fish oil drug has been recommended by FDA for wider market approval
Amarin president named US EY Entrepreneur of the Year for life sciences
John Thero, CEO of fish-oil drug specialist, accepts award for Irish-domiciled company
Shares jump 15% in Ireland’s Amarin on hopes for heart drug
Strong increase in proft forecast on the back of sales of fish oil drug in the US
Amarin president named EY Entrepreneur of the Year
John Thero of the fish oil drug specialist recognised for company’s drug, Vascepa
Amarin jumps on FDA priority review for heart drug
Irish company’s Vascepa on track for earlier than expected approval
Amarin’s heartwarming bulletin for firm’s shareholders
Stock advances over fivefold in 12 months on evidence of medicine’s cardiovascular effect
Amarin to seek European approval for heart drug Vascepa
Clinical trials show Irish company’s fish-oil drug cut incidence of heart attacks and strokes
Business 2018: the winners and the losers
The last 12 months proved to be another year of mixed fortunes in corporate Ireland
Irish firm Amarin confirms heart drug success
Some concern over neutrality of placebo and whether it might have boosted Vascepa data
Amarin surges as trial results exceed expectations
Company’s Vascepa drug proves effective in reducing risk from stroke and heart attack
Amarin reports strong sales growth for Vascepa
Company targets expanded market share for fish oil drug that cuts risk of heart disease
Irish drug company Amarin defeats FDA in US lawsuit
US court rules regulator cannot bar company promoting off label use for drug
Amarin takes legal action against FDA over patent protection for Vascepa
Company continues to fight regulator as it reports $166m loss in first year of commercial operation for fish oil drug
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Election 2024
Full general election coverage including analysis and results for all 43 constituencies
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices